
簡(jiǎn)要描述:Ranitidine hydrochloride 66357-59-3Ranitidine Hydrochloride is a member of the class of histamine H2-receptor antagonists with antacid activity
產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 66357-59-3 |
|---|---|---|---|
| 分子式 | C13H23ClN4O3S | 純度 | ≥98% |
| 分子量 | 350.86 | 貨號(hào) | abs47027355 |
| 規(guī)格 | 100mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a member of the class of histamine | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Ranitidine hydrochloride 66357-59-3
| 產(chǎn)品描述 | |
| 描述 | Ranitidine Hydrochloride is a member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked. |
| 純度 | ≥98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 鹽酸lei尼替丁 |
| 外觀 | Off-white to yellow solid |
| 可溶性/溶解性 | DMSO :70 mg/mL (199.51 mM) Water :70 mg/mL (199.51 mM) |
| 生物活性 | |
| 靶點(diǎn) | Histamine H2 receptor |
| In vitro(體外研究) | Ranitidine sensitizes hepatocytes to killing by cytotoxic products from activated neutrophils, whereas Famotidine lacks this ability. Ranitidine inhibits the production of tumor necrosis factor-alpha (TNF-alpha) in monocytes stimulated with lipopolysaccharide in vitro. Ranitidine reduces the Kel of morphine dose-dependently with a maximum effect of 50%, and increases the relative concentration of morphine-6-glucuronide to morphine-3-glucuronide in isolated guinea pig hepatocytes. Ranitidine gradually decreases the morphine-3-glucuronide/morphine-6-glucuronide ratio by up to 21%. |
| In vivo(體內(nèi)研究) | Ranitidine results in liver injury as evidence by increased in serum alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase activities within 6 hours after Ranitidine administration in rats. Ranitidine inhibits hepatic ischemia/reperfusion-induced increase in hepatic tissue levels of TNF-alpha, cytokine-induced neutrophil chemoattractant, and hepatic accumulation of neutrophils in rats. Ranitidine cotreatment enhances LPS-induced coagulation prior to liver injury, and anticoagulants reduce liver damage in LPS/RAN-treated rats. Ranitidine /LPS-treated rats results in the formation of fibrin clots in liver sinusoids, and prevention of fibrin deposition associated with reduced hepatocellular injury. Ranitidine cotreatment enhances the LPS-induced TNF increase before the onset of hepatocellular injury in rats. Ranitidine displays anxiolytic effects in the elevated plus-maze as indicated by an increase in time spent in the open arms, more open-arm scanning and more end-excursions in rats. |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
